Relationship between serum apolipoproteins levels and retinopathy risk in subjects with type 2 diabetes mellitus
- 43 Downloads
Prognostic significance of apolipoproteins in diabetic retinopathy risk has not been well investigated. The aim of this study was to reveal the relationship between the risk of diabetic retinopathy and the levels of several apolipoproteins and their ratios in a 10-year prospective cohort.
A total of 1023 diabetic patients without retinopathy were selected from a 10-year hospital-based diabetic cohort. In this cohort, all subjects had type 2 diabetes. Blood samples were obtained, and serum levels of several apolipoproteins were measured. In the follow-up period, diabetic retinopathy was diagnosed by two ophthalmologists through a series of ophthalmologic examinations. A Cox proportional hazard analysis was adopted to determine the relationship between the risk of diabetic retinopathy and the levels of several apolipoproteins and their ratios.
In the follow-up period, 315 diabetic patients were suffered from diabetic retinopathy, and the remaining 708 patients did not. Baseline serum level of apoAI ≥ 7.4 μmol/L was related to the decreased risk of diabetic retinopathy (HR 0.86, 95% CI 0.70–0.99). Baseline levels of apoCIII ≥ 6.3 μmol/L, apoE ≥ 1.1 μmol/L, apoCIII-to-apoAI ratio ≥ 0.9 and apoE-to-apoAI ratio ≥ 0.2 were associated with the increased risk of this complication (HR 1.25, 95% CI 1.04–1.49; HR 1.23, 95% CI 1.03–1.47; HR 1.34, 95% CI 1.11–1.60; HR 1.21, 95% CI 1.01–1.46).
Elevated level of apoAI might be a protective factor for diabetic retinopathy. Increased levels of apoCIII, apoE, apoCIII-to-apoAI and apoE-to-apoAI ratios might be risk factors for this complication.
KeywordsApolipoproteins Diabetes mellitus Diabetic retinopathy Lipids Prognosis
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1975, as revised in 2008.
Statement of informed consent
Informed consent was obtained from all patients for being included in the study.
- 2.World Health Organization (2016) Global Report on Diabetes, GenevaGoogle Scholar
- 12.Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d’Emden MC, Crimet DC, O’Connell RL, Colman PG, FIELD Study Investigators (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687–1697CrossRefPubMedGoogle Scholar
- 26.Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, DCCT/EDIC Research Group (2005) Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complicat 19(1):18–25CrossRefPubMedGoogle Scholar
- 28.McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, INTERHEART Study Investigators (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372:224–233CrossRefPubMedGoogle Scholar